• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

PharmaLundensis

0.06 SEK

-2.17 %

Less than 1K followers

PHAL

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.17 %
-42.02 %
-70.74 %
-74.31 %
-81.84 %
-84.20 %
-85.10 %
-91.35 %
-98.07 %

PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Read more
Market cap
4.06M SEK
Turnover
14.85K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
25/6
2026

General meeting '26

20/8
2026

Interim report Q2'26

19/11
2026

Interim report Q3'26

Press release6/4/2026, 12:07 PM

PharmaLundensis: Komplettering till Årsredovisning för 2025

PharmaLundensis
Regulatory press release6/4/2026, 11:05 AM

Årsredovisning för PharmaLundensis AB (publ) 556708-8074 Räkenskapsåret 2025-01-01 - 2025-12-31

PharmaLundensis
Regulatory press release5/28/2026, 2:10 PM

PharmaLundensis: Kvartalsrapport 2026-01-01 till 2026-03-31

PharmaLundensis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/21/2026, 7:02 PM

Kallelse till årsstämma i PharmaLundensis AB

PharmaLundensis
Press release5/20/2026, 8:03 AM

PharmaLundensis: Senarelägger Q1 rapport till torsdag den 28 Maj

PharmaLundensis
Press release4/20/2026, 10:23 AM

PharmaLundensis: Tidsplan för frivillig avnotering av aktie från Spotlight

PharmaLundensis
Press release4/17/2026, 3:27 PM

PharmaLundensis: Vidare information kring avnotering av aktie från Spotlight

PharmaLundensis
Press release3/30/2026, 5:58 PM

PharmaLundensis: Publicering av uppdaterad Internationell Affärsplan

PharmaLundensis
Press release3/30/2026, 8:49 AM

PharmaLundensis: Huvudägare kommer föreslå avnotering av aktie från Spotlight

PharmaLundensis
Press release3/17/2026, 2:45 PM

PharmaLundensis: Presenterar internationell Affärsplan

PharmaLundensis
Press release3/17/2026, 12:42 PM

PharmaLundensis: Registrering av företrädesemission hos Bolagsverket klar

PharmaLundensis
Regulatory press release2/23/2026, 3:38 PM

PharmaLundensis: Nyemission tecknades för ca 2,14 miljoner kronor

PharmaLundensis
Press release2/5/2026, 1:27 PM

PharmaLundensis: Publicering av emissionshandlingar och start av teckningstid

PharmaLundensis
Regulatory press release2/5/2026, 9:43 AM

PharmaLundensis: BOKSLUTSKOMMUNIKÉ 2025-01-01 till 2025-12-31

PharmaLundensis
Press release2/4/2026, 4:46 PM

PharmaLundensis: Tidigarelagd publicering av Bokslutskommuniké till torsdag den 5:e februari

PharmaLundensis
Regulatory press release1/23/2026, 9:49 AM

PharmaLundensis: Genomför företrädesemission på maximalt ca 20,0 MSEK och tidigarelägger bokslutskommuniké till 6 februari

PharmaLundensis
Regulatory press release11/20/2025, 6:20 PM

PharmaLundensis: Kvartalsrapport 2025-07-01 till 2025-09-30

PharmaLundensis
Press release10/6/2025, 1:13 PM

PharmaLundensis: Uppdatering om försäljning av Minievaporatorer

PharmaLundensis
Press release9/17/2025, 7:48 AM

PharmaLundensis: AstraZenecas Fasenra inte bättre än placebo mot KOL

PharmaLundensis
Press release9/5/2025, 1:16 PM

PharmaLundensis: Registrering av företrädesemission hos Bolagsverket klar

PharmaLundensis